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httpClinical signiﬁcance of type II endoleaks after
thoracic endovascular aortic repair
Moritz S. Bischoff, MD,a Philipp Geisbüsch, MD,a Drosos Kotelis, MD,a Matthias Müller-Eschner, MD,b
Alexander Hyhlik-Dürr, MD,a and Dittmar Böckler, MD,a Heidelberg, Germany
Background: To evaluate the clinical signiﬁcance of type II endoleaks (ELII) after thoracic endovascular aortic repair
(TEVAR).
Methods: From January 1997 to June 2012, a total of 344 patients received TEVAR in our institution. ELII was diag-
nosed in 30 patients (8.7%; 13 males; median age: 65 years, range: 24 to 84 years), representing the study population of
this retrospective, single-center analysis. Mean follow-up was 29.5 months (range, 8 months to 9.5 years).
Results: Primary ELII was observed in all but two cases (28/30; 93.3%). The most common sources of ELII were the left
subclavian artery (LSA; 13/30; 43.3%) and intercostal/bronchial vessels (13/30; 43.3%), followed by visceral arteries
(4/30; 13.4%). Overall mortality was 33.3% (10/30). ELII-related death (secondary rupture) was observed in 20%
(2/10). Reintervention (RI) procedures for ELII were performed in 9 of 30 patients (30.0%); 5 of 9 (55.6%) in
cases with ELII via the LSA. Indications for RI were diameter expansion in ﬁve and extensive leakage in four cases.
Treatment was successful in ﬁve patients (55.6%) but failed in four cases (44.4%). In 12 of 21 (57.1%) untreated patients,
ELII sealed during follow-up. In conservatively treated patients, an increase in aortic diameter has been only observed in
a patient with secondary ELII.
Conclusions: The results presented herein suggest that the clinical impact of ELII after TEVAR must not be under-
estimated. Albeit a transient ﬁnding in most cases, ELII is associated with a relevant RI rate, particularly in cases involving
the LSA. RI seems indicated in patients with increasing aortic diameter and/or extensive leakage. Careful surveillance of
all patients with ELII is recommended. (J Vasc Surg 2013;58:643-50.)Thoracic endovascular aortic repair (TEVAR) has
become the treatment option of choice for a wide variety
of thoracic aortic pathologies.1 Despite the proven short-
and midterm safety and efﬁcacy, there is still concern on
the durability of this minimally invasive modality. Data
from single-center studies show considerable reinterven-
tion (RI) rates after TEVAR, ranging from 12% to 22%,
notably attributable to progression of the aortic disease
and endoleak (EL) formation.2-4
Whereas type I and III ELs are regarded as treatment
failures and warrant immediate further treatment, type II
endoleaks (ELII) are usually considered as benign.5 In
contrast to endovascular repair of abdominal aortic aneu-
rysms, where ELII has been studied in detail, speciﬁc
data on clinical signiﬁcance and implications of ELII in
TEVAR are limited.6-8 The aim of the present study was,
therefore, to analyze clinical signiﬁcance and treatment of
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Data source. The study design represents a retrospec-
tive single-center analysis. All patients who receive TEVAR
at the authors’ institution are entered into a prospectively
maintained departmental database. For the underlying
study investigating ELII after TEVAR, the contemporane-
ously collected demographic, preoperative clinical, and
operative data as well as follow-up (FU) information
were analyzed and supplemented from patient records and
computed tomography (CT) data. An Institutional Review
Board approved the study. CT data were interdisciplinary
and consensually evaluated at the time of FU before being
entered into the database. Computed tomographic angio-
graphy (CTA) data of patients diagnosed with ELII were
additionally reviewed by an attending vascular surgeon and
an attending radiologist in an independent fashion.
Study population. Between March 1997 and June
2012, a total of 344 patients underwent TEVAR for various
aortic pathologies. ELII were detected in 30 of 344 cases
(30/344; 8.7%; Fig 1). The indications for TEVAR in the
entire cohort as well as in the 30 patients diagnosed with
ELII are detailed in Table I. The comorbidities and the
procedure-related data for the 30 patients with ELII (13
men, 17 women) are summarized in Table II. The median
age was 65 years (range, 24 to 84 years). Median FU was
29.5 months, ranging from 8 months to 9.5 years. Oper-
ative data are summarized in Table III.
Operative details. The implantation protocol has
been previously published.3 At the authors’ institution,
simultaneous plug occlusion of the left subclavian artery
(LSA) is performed in selected cases, in which an adequate643
Fig 1. Overview of type II endoleaks (ELIIs) observed in a total of 344 thoracic endovascular aortic repair (TEVAR)
cases. BA, Bronchial artery; CA, celiac axis; ICA, intercostal artery; LSA, left subclavian artery; PA, phrenic artery;
SA, splenic artery.
Table I. Indications for TEVAR and ELII distribution
All patients (N ¼ 344) ELII patients (N ¼ 30)
Total,
No. (%)
Elective,
No. (%)
Urgent/
emergent,
No. (%)
Total,
No. (%)
Elective,
No. (%)
Urgent/
emergent,
No. (%) ELII sourcea
TAA 86 (25.0) 46 (53.5) 30 (46.5) 7 (23.3) 4 (57.1) 3 (42.9) LSA (n ¼ 3)2, IC (n ¼ 3),
BC (n ¼ 1)
PAU 57 (16.6) 33 (57.9) 24 (42.1) 6 (20.0) 1 (16.7) 5 (83.3) LSA (n ¼ 3)1, IC (n ¼ 1),
BC (n ¼ 1), CA (n ¼ 1)1
TAAA 54 (15.7) 36 (66.7) 18 (33.3) 10 (33.3) 6 (60.0) 4 (40.0) IC (n ¼ 4)1, LSA (n ¼ 2)1,
CA (n ¼ 2)1, SA (n ¼ 1),
BC (n ¼ 1)
ADB 79 (23.0) 37 (46.8) 42 (53.2) 3 (10.0) 1 (33.3) 2 (66.7) LSA (n ¼ 3)1
Acute 39 (11.3) 9 (23.1) 30 (76,9) 2 (66.7) - 2 (100.0)
Chronic 40 (11.6) 28 (70.0) 12 (30.0) 1 (33.3) 1 (100.0) -
AT 22 (6.4) - 22 (100.0) -
IMH 17 (4.9) 8 (47.1) 9 (52.9) -
ABF 14 (4.1) - 14 (100.0) 1 (3.3) - 1 (100.0) LSA (n ¼ 1)
ADA 5 (1.5) - 5 (100.0) -
PA 7 (2.0) 4 (57.1) 3 (42.9) 2 (6.6) 2 (100.0) - LSA (n ¼1), PA (n ¼ 1)
ICA 1 (0.3) - 1 (100.0) -
LAA 1 (0.3) 1 (100.0) - -
LSAA 1 (0.3) 1 (100.0) - 1 (3.3) 1 (100.0) - LSA (n ¼ 1)1
Totals 344 (100.0) 166 (48.3) 178 (51.7) 30 (100.0) 15 (50.0) 15 (50.0)
ABF, Aortobronchial ﬁstula; ADA, aortic type A dissection; ADB, aortic type B dissection; AT, aortic transaction; BC, bronchial artery; CA, celiac axis; ELII,
type II endoleak; IC, intercostal artery; ICA, intercostal artery aneurysm; IMH, intramural hematoma; LAA, arteria lusoria aneurysm; LSAA, left subclavian
artery aneurysm; PA, patch aneurysm; PAU, penetrating aortic ulcer; RI, reintervention; SA, splenic artery; TEVAR, thoracic endovascular aortic repair.
aThe superscript numbers indicate the number of RIs performed for a speciﬁc type of ELII in the underlying aortic pathology.
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expected, namely in pathologies involving the origin of
the LSA (zones 2 and 3).9 The LSA revascularization is
selectively undertaken, preferably using subclavian-carotid
transposition.10
The preoperative and postoperative (FU) CTA scans
were preferably performed following a standardized TEVAR
protocol containing 1-mm slice acquisition of the entire
aorta, arterial, venous, and delayed venous imaging phases
as well as three-dimensional image reconstructions (Siemens
Somatom; Siemens, Erlangen, Germany). FU included
medical history, physical examination, and CTA before
discharge, 6 months, 1 year, and annually thereafter in
uneventful cases. In complicated cases, FU was adjusted
accordingly.
Deﬁnitions. The deﬁnitions used in this study meet
the reporting standards for TEVAR published in 2010 bythe Society of Vascular Surgery.11 ELII was deﬁned as
retrograde perfusion via branch vessels (aortic aneurysm) or
perfusion of the false lumen via the overstented LSA (aortic
dissection). In patients with aortic dissection, retrograde
ﬂow from distal entry tears were not considered as ELs.5,11
Primary ELII was deﬁned as an EL present at the im-
plantation or initially diagnosed during the 30-day post-
operative period. In contrast, every ELII detected after
successful TEVAR and an uneventful perioperative interval
was deﬁned as a secondary ELII.12 RI for ELII was deﬁned
as the need to perform additional surgical or interventional
procedures to achieve EL sealing. At the authors’ institu-
tion, the following conditions represent indications for
RI: (1) enlargement of the aneurysmal sac ($5 mm/6 mo)
in the setting of an ELII and (2) ELII originating from
large-caliber vessels (ie, LSA/visceral arteries) with CT
morphologic signs of pressurizing ﬂow (large EL cavity/
Table II. Characteristics of patients with ELIIs (n ¼ 30)
No. %
Patient population 30
Median age, years 65
Age range, years 28-84
Male sex 13 43.3
Patients $ ASA III 27 90.0
Previous cardioaortic surgery 9 30.0
Comorbidities
Hypertension (arterial) 30 100.0
Smoking 17 56.7
Coronary artery disease 8 26.7
COPD 7 23.3
Diabetes 3 10.0
Renal insufﬁciency 4 13.3
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease; ELII, type II endoleak.
Table III. Operative data of patients with ELIIs (n¼ 30)
Variable
No. (%) or
median (range)
Treatment period (total no. TEVAR)
1997-2001 (51) 2 (6.7)
2002-2006 (115) 13 (43.3)
2007-2011 (165) 15 (50.0)
Until 6/2012 (13) 0 (0.0)
Procedural details
Elective status 15 (50.0)
Urgent status 8 (26.7)
Emergent status 7 (23.3)
Hybrid procedures
Arch hybrid 6 (20.0)
TAA/A hybrid 5 (16.6)
Combined arch/TAA/A hybrid 3 (10.0)
ELII, Type II endoleak; TAA, thoracic aortic aneurysm; TAAA,
thoracoabdominal aortic aneurysm; TEVAR, thoracic endovascular aortic
repair.
Fig 2. Double-oblique multiplanar reconstruction (MPR) of
computed tomographic angiography (CTA) after thoracic endo-
vascular aortic repair (TEVAR) shows a type II endoleak (ELII)
originating from the left subclavian artery (LSA) (arrow).
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Diameter expansions are detailed as increase of aortic
diameter over time (mm/interval between CTA scans).
Expansion was assessed by comparing the CTA before
discharge to subsequent FU scans.
Statistical analysis. Data were entered in spreadsheets
(Microsoft Excel for PC, 2003; Microsoft, Redmond,
Wash) and transferred to PASW Statistics (v. 18.0; IBM
Corporation, Somers, NY) for description and analysis.
Patient and disease characteristics are described as percent-
ages or median (range). Based on Kaplan-Meier analysis,
the log-rank test was used for survival comparisons.
RESULTS
Primary and secondary ELII. The overall ELII rate
was 8.7% (30/344; Fig 1 and Table I). Primary ELII was
observed in 28 (28/30; 93.3%) cases. Secondary ELII was
seen in two patients (2/30; 6.7%). In both cases, the EL
originated from an intercostal artery. In the ﬁrst patient,the EL was observed 2 years after TEVAR for thor-
acoabdominal aortic aneurysm (TAAA), whereas in the
second case, it was detected 10 years after TEVAR for
thoracic aortic aneurysms (TAAs).
ELII via the covered LSA. Coverage of the LSA was
performed in 129 of 344 patients (37.5%; Fig 2). Primary
LSA revascularization was undertaken in 46 of 129 cases
(35.6%). ELII originating from the nonrevascularized LSA
was seen in 13 of 83 covered, but nonrevascularized cases
(15.6%) and represents the most common single source
of ELII in this study (13/30; 43.3%).
The EL-related RI rate in patients with ELII via the
covered LSA was 38.5% (5/13), accounting for more
than the one-half of all RIs attributable to ELII (5/9;
55.6%; Table IV).
ELII via intercostal, bronchial, and phrenic
arteries. Intercostal arteries (n ¼ 9), bronchial arteries
(n ¼ 3), and phrenic arteries (n ¼ 1) were responsible
for 43.3% of all detected ELII (30.0%, 10.0%, and 3.3%,
respectively). RI was required in two cases with ELII orig-
inating from intercostal arteries, leading to an RI rate of
22.2% (2/13; 15.4%; Table IV and Fig 3).
ELII via visceral arteries. In four cases (4/30;
13.4%), the celiac trunk or its branches could be identiﬁed
as a source of ELII (Fig 4). In the ﬁrst patient, the EL
originated directly from the celiac trunk, which had not
been ligated during an emergency hybrid TAAA procedure
with overstenting of the celiac trunk to expand the distal
landing zone. In the second case, equally a hybrid TAAA
repair, there was an ELII despite intraoperative ligation
of the celiac trunk, most probably because it had been
ligated too distally. In the third case, performed under
Table IV. Case-by-case presentation of RIs performed due to ELIIs (n ¼ 9)
Patient
no.
Sex/age,
years Diagnosis
ELII
source Indication RI performed
Interval
OP-RI, days
RI
Success FU
1 Female/49 TAA LSA Suspected
pressurizing EL
Surgical LSA clipping 12 N Conversion
2 Female/73 PAU CT Suspected
pressurizing EL
ST/coiling 3 Y c
3 Female/68 TAAA CT Diameter expansion and
rupture
(12 mm/69 days)
ST/coiling 151 a
4 Male/68 TAAA LSA Suspected
pressurizing EL
LSA transposition 17 Y c
5 Female/63 TAAA ICA Diameter expansion
(10 mm/48 months)
Coiling 1461 N Conservative; b
6 Male/78 TAA LSA Diameter expansion
(5 mm/61 days)
AVP
(12 mm)
29 Y c
7 Male/70 LSAA ICA Diameter expansion
(23 mm/29 months)
BP þ prox. TEVAR 870 N Conversion; a
8 Male/58 PAU LSA Suspected
pressurizing EL
AVP
(14 mm)
2 Y c
9 Male/40 ADB LSA Diameter expansion
(5 mm/6 months)
AVP
(16 mm)
244 Y c
Type Ia EL
ADB, Aortic type B dissection; AVP, Amplatzer vascular plug; BP þ prox, carotid, carotidal bypass and proximal TEVAR extension; CT, celiac trunk; EL,
endoleak; ELII, type II endoleak; FU, follow-up; ICA, intercostal artery; LSAA, left subclavian artery aneurysm; N, no; OP, operation; PAU, penetrating
aortic ulcer; RI, reintervention; ST, sclerotherapy; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TEVAR, thoracic endovascular
aortic repair; Y, yes.
aIntraoperative death.
bEL still present.
cEL resolved.
Fig 3. Axial image (A) and double-oblique multiplanar reconstruction (MPR) of computed tomographic angiography
(CTA) (B) demonstrate a type II endoleak (ELII) originating from an intercostal artery (arrow). As shown in the axial
image in (C) the EL was treated by computed tomography (CT)-guided embolization (patient no. 5; Table III).
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ally overstented after previous visualization of the patent
pancreaticoduodenal artery to verify sufﬁcient collateral
blood ﬂow.13 In an additional hybrid TAAA case, ELII via
the patent splenic artery was observed, most probably
attributable to clip dislocation. Treatment was indicated
in two of four patients with visceral ELII, yielding an RI
rate of 50% in this subgroup (Table IV).
Mortality. Overall mortality of the entire cohort was
34.8% (120/344), whereas the mortality rate among
patients with ELII was 33.3% (10/30). The occurrence ofELII did not inﬂuence survival (log-rank test: P ¼ .651).
Thirty-day mortality was 10.0% (3/30). No perioperative
death was EL related. One patient died of multiorgan failure
on the ninth postoperative day. Another patient died of
pneumonia 26 days after endovascular exclusion of a pene-
trating aortic ulcer. In a patient who passed away 29 days
after TEVAR of a contained ruptured TAA, the cause of
death remains unclear.
Long-term mortality was 25.9% (7/27). Four of seven
long-term deaths are considered to be procedure-related.
At least two of these cases were mediated by ELII:
Fig 4. Double-oblique multiplanar reconstruction (MPR) of
computed tomographic angiography (CTA) after thoracic endo-
vascular aortic repair (TEVAR) reveals a type II endoleak (ELII)
(arrow) originating from the celiac trunk.
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151 days after hybrid TAAA repair during her RI procedure
attributable to rupture of the aneurysmal sac, which was
continuously supplied by an ELII originating from the
celiac axis. A 70-year-old patient (patient no. 7; Table IV)
died of multiorgan failure after emergent conversion with
open descending repair attributable to contained rupture
of an aneurysmatic LSA. The pathology had been initially
treated by TEVAR but was still perfused via an ELII. A
third, 76-year-old female patient died of an internal
bleeding 56 months after endovascular TAA exclusion.
The patient was known to have an ELII via a bronchial
artery; however, FU-CTA did not show sac enlargement.
In the remaining four patients, the cause of death is
unrelated to ELII. Instead, causes of death were intestinal
perforation, mediastinitis, pneumonia, and stroke (n ¼ 1,
each).
RIs for ELII. The RI rate was 30.0% (9/30). In total,
11 procedures (seven interventional RIs, two surgical RIs,
and two late conversions) were performed in nine patients.
Table IV summarizes the data in a case-by-case fashion. In
ﬁve of nine patients (55.6%), the indication for RI was
diameter expansion. In the four remaining cases (44.4%),
RIs were performed because of large EL cavities, suggesting
a pressurizing leak (Table IV). The median interval bet-
ween the TEVAR procedure and the RI was 54 days (range,
3 days to 48 months). Treatment of ELII was successfully
undertaken in ﬁve of nine cases (55.6%) but failed in four
patients (44.4%). Two of these four patients underwent
late conversion, yielding a conversion rate of 6.6% (2/30).
The ﬁrst conversion (open aortic arch replacement) was
undertaken in 2001 in a patient (patient no. 1; Table III),who had initially undergone TEVAR for TAA repair. In the
postoperative CT scan, an extensive ELII via the inten-
tionally covered LSA was detected. Surgical clipping of the
LSA was performed 12 days after TEVAR. However,
subsequent imaging still demonstrated the ELII. As the
patient demanded for deﬁnite repair, elective conversion
was undertaken 134 days later. The second conversion was
emergently performed in a patient with an LSA aneurysm,
who had initially undergone TEVAR with simultaneous
LSA plug occlusion (patient no. 7; Table III). FU-CTA
demonstrated ongoing aneurysm growth (average expan-
sion of 5 mm/6 mo), which was thought to be type Ia EL
related. Therefore, the patient underwent carotid-carotidal
bypass in conjunction with TEVAR proximalization
29 months after the index procedure. Nevertheless, further
imaging studies detected ongoing sac enlargement,
supplied by an intercostal artery neighboring the occluder
plug. In an interdisciplinary board (vascular surgery, cardiac
surgery, and radiology), open distal arch and proximal
descending repair was suggested as the treatment option of
choice. However, the patient initially refused surgery and
did not present until contained rupture had occurred
18.5 months after his RI procedure.
Spontaneous course of ELII. A total of 21 cases
(21/30; 70.0%) with ELII were conservatively treated. In
12 of 21 patients (57.1%), the EL sealed spontaneously
during FU (LSA: n ¼ 5, intercostal artery: n ¼ 5, bronchial
and phrenic artery: n ¼ 1, each). ELII was detectable for
a median of 106 days (range, 10 days to 15 months). In
none of these patients, CTA revealed an increase of aortic
diameter during FU. In the ﬁve cases involving the LSA,
imaging suggested only marginal leakage. Thus, the
patients were conservatively treated.
Six patients (6/21; 28.6%) with an ELII in their last
CTA scan died during FU (LSA: n ¼ 3; bronchial artery:
n ¼ 1; celiac trunk: n ¼ 2). The EL had been present for
a median of 24 days (range, 1 day to 40 months). In one
of these patients (TEVAR for contained ruptured TAA),
RI was indicated due to a large ELII cavity via the LSA.
However, the patient died 29 days after discharge. One
patient (1/21; 4.8%) with primary ELII (bronchial artery:
n ¼ 1) is known to be alive but lost to FU since discharge
from hospital. At the time of discharge, he was not sched-
uled for RI.
As previously described, there are two patients with
secondary ELII (2/21; 9.5%; intercostal arteries in both
cases). The ﬁrst patient (TEVAR for TAAA) is under
surveillance with no sac enlargement detected so far. In
the second, previously stable, patient (TEVAR for TAA),
a 4-mm increase of aortic diameter was detected between
the last regular scan and the following scan, depicting
ELII (scan interval, 16 months). As the diameter remained
stable within the last year of FU, the patient is currently
treated conservatively.
Additional EL and RI procedures performed. In the
30 patients diagnosed with ELII, simultaneous occurrence
of a type Ia EL and ELII has been observed in three patients.
In the ﬁrst patient (contained ruptured TAA), successful
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Regarding the ELII via the LSA, elective RI was indicated.
However, the patient died 29 days after discharge. Patient
no. 9 (Table IV) had a complex endoleak situation consist-
ing of a type Ia EL in conjunction with an ELII via the LSA.
The patient is currently scheduled for type Ia EL repair.
Patient no. 5 (Table IV) underwent TEVAR proximaliza-
tion for a type I EL 171 days after the initial TEVAR
procedure (1290 days prior to her RI for ELII via an
intercostal artery). Recently, FU-CTA detected a type III
EL in the TAA patient with secondary ELII. The patient
underwent successful endovascular relining. In a patient
with TEVAR for aortobronchial ﬁstula (ELII via the LSA,
resolved spontaneously), FU-CTA detected a ﬂoating
thrombus in the descending aorta, which was covered by
stent graft implantation 852 days after the index procedure.
DISCUSSION
The present study shows that ELII is a frequent obser-
vation, occurring in about 9% of our TEVAR patients
(30/344). Despite the fact that the majority of cases in
this series were conservatively managed, we observed an
ELII associated RI rate of 30%, thus, illustrating the impact
of ELII on clinical practice. Furthermore, the results
underline the need for careful monitoring in patients diag-
nosed with ELII after TEVAR.
Overall EL rates after TEVAR range between 5% and
35%.8,14,15 ELII after TEVAR is reported to occur in
around 5% to 10% of cases, which is in line with our ﬁnd-
ings.16-19 Albeit the occurrence of ELII is regularly re-
ported in publications on TEVAR, speciﬁc details (ie,
anatomic sort, RI rate, type of RIs performed, associated
aortic diameter enlargement) allowing for data interpreta-
tion are frequently missing. In contrast to the herein pre-
sented study, with secondary interventions performed in
about every third patient with ELII, the RI rates reported
in the literature mostly range below 5%.4,8,14,20
In this study, we observed ELII-mediated fatal aneu-
rysm rupture in two cases, both illustrating potential chal-
lenges associated with ELII. In the ﬁrst patient (patient no.
3; Table IV), two consecutive FU scans showed diameter
expansion, caused by an ELII via the celiac trunk, which
had not been ligated 151 days earlier during a hybrid
TAAA repair. The patient was scheduled for elective trans-
catheter EL embolization but experienced contained rup-
ture before and died of hypovolemic shock during the
emergently performed RI procedure. The case underlines
the fact that the dynamics of ELII must not be underesti-
mated. Furthermore, it supports the notion that in patients
with diameter expansion, a rather aggressive treatment
strategy seems to be indicated.
The second patient had undergone TEVAR in
conjunction with LSA plug occlusion for an aneurysmatic
LSA (patient no. 7; Table III). FU-CTA detected an EL.
However, imaging failed to precisely characterize the type
of EL (type Ia/c vs ELII). Due to diameter expansion,
the patient underwent carotid-carotidal bypass and TEVAR
proximalization. As CTA still showed aneurysm growth,the patient underwent diagnostic transbrachial angiog-
raphy, which ruled out type Ic EL but revealed an ELII
in terms of an intercostal artery neighboring the occluder.
Open conversion, in general, rarely indicated after TEVAR,
was recommended by an interdisciplinary board.15,21
Unfortunately, the patient did not present until contained
rupture had occurred. The case illustrates that characteriza-
tion of ELII by CTA can be challenging, especially in the
aortic arch. If necessary, the use of additional imaging
modalities (ie MRA, DynaCT, and/or conventional angi-
ography) is indicated to resolve complex EL situations
(eg, the combination of a type Ia and an ELII via the
LSA), which we observed in patient no. 9 (Table IV).22,23
Coverage of the LSA is necessary to achieve proximal
seal in up to 40% of patients treated with TEVAR.24 There-
fore, the risk of ELII and the potential need for RI must be
taken into account if coverage of the (nonrevascularized)
LSA is performed during TEVAR. Along with others, we
believe that ELII via a comparably large-diameter vessel
as the LSA, requires special attention.5,22,25 Besides the
two patients with increased aortic diameter, we treated
three more patients with ELII via the LSA, in whom early
postoperative imaging did not detect diameter expansion
(Table IV). In fact, CTA showed a strong contrast en-
hancement in the arterial and the venous phase suggesting
a pressurizing leakage (Fig 2). Nowadays, transbrachial
plug occlusion can be favorably used to treat ELII via the
LSA.26 In our series, all vascular plug implantations were
successful (Table IV). However, simultaneous occlusion
of the LSA during TEVAR to prevent ELII formation is
not performed at our institution, as ELII was only seen
in around 15% (13/83) of covered, nonrevascularized,
cases. In retrospect, plug occlusion would have been also
the treatment of choice for the RI performed in patient
no. 2 (Table IV). However, in 2001 vascular plugs were
not yet available at our institution.
ELII via the celiac axis or intercostal arteries is favor-
ably approached by EL embolization by coils and/or liquid
embolic agents (ie, n-butyl cyanoacrylate or ethylene vinyl
alcohol).27-29 The procedure can be performed percutane-
ously through a transarterial or translumbar/transthoracic
approach. In our series, a 67-year-old female with an
ELII via an intercostal artery after hybrid TAAA repair
was interventionally treated by CT-guided punction of
the aneurysm sac and subsequent application of multiple
coils (patient no. 5; Table III; Fig 3). The EL located at
the distal arch had been persistent for about 4 years and
had led to ongoing aneurysm growth (10 mm/48 mo)
up to 8.5 cm in diameter. Postinterventional CTA showed
shrinkage of the aneurysm sac, justifying a “watchful wait-
ing” strategy.
As in endovascular repair for abdominal aortic aneu-
rysms, there is no data-driven consensus to support any
threshold for RI in ELII after TEVAR.15,30 What we
have learned from the cases reported herein is that not
only treatment of ELII can be challenging but also visual-
ization and evaluation of RI eligibility. From our experi-
ence, progressive diameter expansion in the setting of
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pendent of diameter expansion, we advocate a prompt
and interdisciplinary RI evaluation in cases of ELII
involving the LSA or visceral branches. If CTA suggests
a pressurizing leakage, RI should be liberally performed.
Regarding small-caliber vessels, such as bronchial or inter-
costal arteries, we favor a “watchful waiting” strategy, as we
and others frequently observed spontaneous thrombosis
during FU.25 In patients with primary ELII, the ﬁrst FU
scan after discharge should be performed within 3 months
postoperatively.
To our knowledge, this is the ﬁrst study directly
addressing the issue of ELII after TEVAR. Nonetheless,
the study has several limitations besides its retrospective
design.
d The herein presented study focuses on clinical impact
and management of ELII after TEVAR. Due to the
limited number of cases available, the heterogeneity
of aortic disease and sources of ELII, a statistical anal-
ysis assessing determinants and risk factors for ELII
was not performed, limiting the informative value of
our results.
d Assessment of EL in aortic dissection is a point of
controversy.11 Continued perfusion of the false lumen
is currently considered “a special circumstance that
may not be directly analogous to EL.” Speciﬁc con-
sensus reporting standards for aortic dissection are still
missing. According to TEVAR criteria published by
the European Association for Cardio-Thoracic Surgery
(EACTS), we did not classify retrograde (cross) ﬂow
from distal entry tears but only antegrade ﬂow from
the LSA into the false lumen as ELII.5
d At the authors’ institution, CTA is the image modality
of choice to diagnose and classify EL. Acquisition of
1-mm slices and multiple phases of imaging are
routinely available since the introduction of helical
CT scanning in clinical practice in the middle of the
last decade. Before that period, CTA might have
underestimated the number of ELII after TEVAR.
As described beforehand, CTA alone can fail to resolve
complex EL situations. With the ongoing improve-
ment of imaging modalities this issue might be further
reduced, facilitating EL evaluation and treatment.
In conclusion, ELII is a common ﬁnding after TEVAR,
which requires interdisciplinary attention. The clinical
signiﬁcance of ELII after TEVAR must not be underesti-
mated, as it is associated with a relevant RI rate. A close
FU is mandatory after TEVAR until EL sealing has
occurred. Clearly, more data are needed to determine the
risk of ELII over time.AUTHOR CONTRIBUTIONS
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